Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

4D Molecular Therapeutics Q2 EPS $(0.63) Beats $(0.71) Estimate, Sales $5.00K Down From $239.00K YoY

Author: Benzinga Newsdesk | August 08, 2024 05:56pm
4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.71) by 11.27 percent. This is a 18.18 percent increase over losses of $(0.77) per share from the same period last year. The company reported $5.00 thousand in sales this quarter. This is a 97.91 percent decrease over sales of $239.00 thousand the same period last year.

Posted In: FDMT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist